AbbVie (ABBV) Notes Payables (2012 - 2025)

AbbVie (ABBV) has 14 years of Notes Payables data on file, last reported at $2.5 billion in Q4 2025.

• Notes Payables for Q4 2025 came in at $2.5 billion, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $2.5 billion (changed N/A YoY), and the FY2025 annual result was $2.5 billion, changed N/A from the prior year.
• Notes Payables slipped to $2.5 billion in Q4 2025 per ABBV's latest filing, from $3.8 billion in the prior quarter.
• Over five years, Notes Payables peaked at $3.8 billion in Q3 2025 and troughed at $1.0 million in Q4 2022.
• A 5-year average of $665.6 million and a median of $14.0 million in 2021 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2022 and 2025: Notes Payables tumbled 92.86% in 2022, then surged 53000.0% in 2025.
• A 5-year view of Notes Payables shows it stood at $14.0 million in 2021, then plunged by 92.86% to $1.0 million in 2022, then jumped by 100.0% to $2.0 million in 2023, then soared by 50.0% to $3.0 million in 2024, then jumped by 83200.0% to $2.5 billion in 2025.
• Business Quant data shows ABBV's Notes Payables at $2.5 billion in Q4 2025, $3.8 billion in Q3 2025, and $2.0 billion in Q2 2025.